Kairos Pharma Business Summary

Kairos Pharma, Ltd. (KAPA) is a clinical-stage biopharmaceutical company utilizing a development-heavy business model focused on reversing cancer drug resistance and immune suppression. The company generates value through its oncology pipeline, primarily segmented into its lead antibody candidate, ENV-105 (targeting CD105), and the KROS series of small molecules and antibodies. While currently pre-revenue, Kairos intends to monetize its assets through future product sales, strategic licensing, and milestone-based partnerships. Its clinical focus targets high-unmet-need areas, including metastatic castration-resistant prostate cancer (mCRPC) and EGFR-mutated non-small cell lung cancer (NSCLC), where it aims to re-sensitize tumors to standard-of-care therapies. Kairos competes with clinical-stage peers such as CytoMed Therapeutics, Longeveron, and Kura Oncology, occupying a unique market niche by developing "re-sensitization" agents that enhance the commercial longevity of existing blockbuster treatments rather than competing as standalone monotherapies. The executive team is led by CEO and Chairman Dr. John S. Yu, a distinguished neurosurgeon and Professor at Cedars-Sinai Medical Center with academic credentials from Stanford, Harvard, and MIT. Scientific strategy is directed by Chief Scientific Officer Dr. Neil Bhowmick, a prominent cancer biologist and Cedars-Sinai professor, alongside VP of Research and Development Dr. Ramachandran Murali, an expert in molecular engineering. Financial operations are managed by CFO Doug Samuelson, a veteran with over 25 years of biopharma leadership. The company’s board features high-profile industry figures including Dr. Michael Keyoung (CBC Group) and Dr. Rahul Singhvi (Resilience; former Flagship Pioneering partner). Kairos is backed by notable institutional investors, including Armistice Capital and Two Sigma Investments, leveraging a deep pedigree in translational medicine and strategic ties to Cedars-Sinai to advance its clinical programs.